Microdose Psychedelic Insights is a cutting-edge media firm that aims to bring the psychedelics sector to the forefront of contemporary medicine by developing appealing content, disseminating financial analyses, and holding interesting industry events. On January 27, 2022, Microdose will host the Psychedelic Capital January Edition.
Attendees will have access to the top firms, most recent IPOs, newest opportunities, and most in-depth market knowledge in the rapidly rising psychedelic medicine sector at the virtual event.
Key Points Covered
This month’s conference features dynamic presentations from Heroic Hearts Project, Entheo Digital, PurMinds NeuroPharma, HAVN Life Sciences Inc. and panel discussions on topics of Public vs Private Markets, and What Will 2022 Look Like.
Heroic Hearts Project offers a proprietary program to veterans who are interested in pursuing psychedelic treatment options. Heroic Hearts Project primarily works with ayahuasca retreat centers due to the powerful effect it has shown to have on healing PTSD. The Heroic Hearts Project program has been designed to ensure veterans get the most out of this valuable opportunity and are set up for success when they return home.
Entheo Digital
Entheo Digital is a digital therapeutics company pursuing the creation of a wellness technology marketplace at the intersection of psychedelic therapy and experiential medicine. The company is growing the accessibility and scalability of psychedelic therapy with immersive virtual experiences.
PurMinds NeuroPharma
PurMinds NeuroPharma is pursuing breakthrough solutions for devastating neurological disorders with a special emphasis on neurodegenerative diseases. We strive to deliver the right drugs to the right patients by utilizing technology and championing next generation drug development approaches. Drug development for neurological disorders has been marred with failure due to imperfect modelling of human diseases in pre-clinical studies and inadequate stratification within patient recruitment for clinical trials. We use multi-omics analyses of diseased and healthy Human iPSC-derived neurons to better understand the pathophysiology of neurodegenerative diseases, which enables us to design personalized, precision neurotherapeutics.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind. Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
Explore the Schedule
*All times are Eastern Standard Time Zone.
1:30pm: Introduction
Featuring Patrick Moher and Richard Skaife.
1:45pm: Doing Good Presentation – Heroic Hearts Project
Featuring Jesse Gould.
2:05pm: Entheo Digital
Featuring Robin Arnott, and Sandeep Prakash.
2:40pm: Public vs Private Markets
Featuring Richard Skaife, Bill O’Hara, and Matthew King.
3:15pm: PurMinds NeuroPharma
Featuring Susan Chapelle, and Janet Qi.
3:50pm: What Will 2022 Look Like
Featuring Cody Shandraw, Sara Brittany Somerset, Tesla La Touche, Doug Drysdale.
04:25pm: HAVN Life Sciences
Featuring Tim Moore.
Additional information about the Psychedelic Capital: January 2022 Conference, as well as details for registration, can be found on the Psychedelic Capital conference website at the following link: https://microdose.buzz/pressrelease
Why You Should Attend
Attendees will be able to form contacts, network with professionals from throughout the psychedelics industry, and learn about intriguing and breakthrough pre-IPO investment opportunities in the field at the conference.
For more information regarding the Psychedelic Capital Jan 27 conference, including registration and complimentary tickets, please visit https://microdose.buzz/pressrelease.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.
